搜索历史清除全部记录
最多显示8条历史搜索记录噢~
全部
  • 全部
  • 产品管理
  • 新闻资讯
  • 介绍内容
  • 企业网点
  • 常见问题
  • 企业视频
  • 企业图册

+
  • epiboxrs.jpg

抗HeV/NiV糖蛋白G抗体(HENV-10)

抗HeV/NiV糖蛋白G抗体(HENV-10),Anti-HeV/NiV Glycoprotein G Antibody (HENV-10),非常适合开展ELISA和中和反应等实验类型。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。


关键词

抗HeV/NiV糖蛋白G抗体(HENV-10)


所属分类


目录号

RVV08008

  • 产品描述
  • 产品组分
  • 文件资源
  • 营销中心
  • 注意事项
  • FAQ
  • 文献追踪
  • Expression system

    Mammalian Cells

    Species reactivity

    Hendra virus (isolate Horse/Autralia/Hendra/1994) & Nipah virus

    Host species

    Human

    Isotype

    IgG1, kappa

    Clonality

    Monoclonal

    Target

    G, Glycoprotein G, Attachment glycoprotein, Receptor binding protein, RBP

    Concentration

    2.3 mg/ml

    Endotoxin level

    Please contact with the lab for this information.

    Purity

    >95% as determined by SDS-PAGE.

    Purification

    Protein A/G purified from cell culture supernatant.

    Accession

    O89343, Q9IH62

    Applications

    ELISA, Neutralization

    Form

    Liquid

    Storage buffer

    0.01M PBS, pH 7.4.

    Stability and Storage

    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

    Clone ID

    HENV-10

  • 产品组分

    内容

    型号

    规格

    储存温度

    抗HeV/NiV糖蛋白G抗体(HENV-10)

    RVV08008-01 100ug -20°C

    抗HeV/NiV糖蛋白G抗体(HENV-10)

    RVV08008-02 1mg -20°C

    操作手册

    1 1

    常温室温

  • 文件资源

    文件下载

    文件内容

    资源说明

    RVV08008-抗HeV/NiV糖蛋白G抗体(HENV-10)

    操作手册

    RVV08008-抗HeV/NiV糖蛋白G抗体(HENV-10)相关单页

    宣传单页

     

  • 营销中心1

  • 注意事项

    保存建议 厂家推荐蓝冰运输。当您收到产品后,按照说明书建议保存于-20°C。

     

  • FAQ

     

  • Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses., PMID:40143282

    Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638

    Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501

    Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562

    Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362

    Structure and design of Langya virus glycoprotein antigens., PMID:38593070

    Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014

    Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525

    Structure and design of Langya virus glycoprotein antigens., PMID:37645760

    Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376

    A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163

    Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063

    Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187

    Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins., PMID:35744614

    Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431

    Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409

    Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres., PMID:34358146

    Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387

    Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487

    Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264

    Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice., PMID:32340278

    Establishment of a Highly Sensitive Assay for Detection of Hepatitis E Virus-Specific Immunoglobulins., PMID:31694975

    A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101

    Superinfective Hepatitis E Virus Infection Aggravates Hepatocytes Injury in Chronic Hepatitis B., PMID:31612388

    An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections., PMID:31570878

    Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice., PMID:31561922

    Rabies-based vaccine induces potent immune responses against Nipah virus., PMID:31016033

    Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody., PMID:30995971

    Protection from Hendra virus infection with Canarypox recombinant vaccine., PMID:29263849

    The Association of Cytokines and Micronutrients with Hepatitis E Virus Infection During Pregnancy and the Postpartum Period in Rural Bangladesh., PMID:26621563

    Structural characterization by transmission electron microscopy and immunoreactivity of recombinant Hendra virus nucleocapsid protein expressed and purified from Escherichia coli., PMID:26196500

    Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus., PMID:25948743

    Rhabdovirus-based vaccine platforms against henipaviruses., PMID:25320306

    Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health., PMID:24572697

    Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus., PMID:24508193

    Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody., PMID:24130486

    Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months., PMID:23867060

    Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins., PMID:22915804

    Periductal induction of high endothelial venule-like vessels in type 1 autoimmune pancreatitis., PMID:22750968

    Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases., PMID:22572886

    Henipavirus mediated membrane fusion, virus entry and targeted therapeutics., PMID:22470837

    Ephrin-B2 and ephrin-B3 as functional henipavirus receptors., PMID:22227101

    A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge., PMID:21689706

    Adaptive immune responses during acute uncomplicated and fulminant hepatitis E., PMID:21143520

    A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system., PMID:21073718

    Targeting of ICAM-1-directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes., PMID:20429814

    A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics., PMID:19646266

    Development of a neutralization assay for Nipah virus using pseudotype particles., PMID:19559943

    Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses., PMID:19216624

    Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding., PMID:18799571

在线留言

如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!

图片名称

艾维缔官网

图片名称
图片名称

艾德官网

图片名称
图片名称

B站IVDSHOW

图片名称
图片名称

抖音军哥聊表观

图片名称
图片名称

视频号艾维缔

图片名称
图片名称

小红书艾维缔

图片名称
图片名称

快手表观盒子

图片名称
图片名称

表观遗传学

图片名称

联系我们

Tel:+86-0313-5935521|18911529660

ADD:张家口市怀来县东花园镇哈工大研究院T8幢709

邮箱:1951545998@qq.com

留言咨询

如果您对我们的产品和服务感兴趣,请留下您的信息。

立即咨询 →

IVDSHOW

订阅我们,以便及时了解产品更新和特惠活动

%{tishi_zhanwei}%
售后反馈 →

免责申明:本网站销售的所有产品均不得用于人类或动物之临床诊断或治疗,仅可用于工业或者科研等非医疗目的。(获得国家相关部门批准的产品除外) 

版权所有:艾维缔科技怀来有限公司 

营业执照